Emerging retatrutide, a dual -action drug targeting equally GLP-1 and GIP receptors, is sparking considerable interest within the healthcare community. Initial clinical trials have demonstrated substantial losses in overall size and improvements in physiological markers for individuals with excess weight . Researchers believe this novel approach… Read More